Platinum Studios Inc. (OTCBB:PDOS) and producer/Platinum Studios Board Member Mark Canton announced that they will be teaming-up to immediately begin work on bringing the Platinum Studios comic book “Atlantis Rising” into an ongoing franchise for the silver screen.  The film is set against an undersea civilization that began over 10,000 years ago, and whose presence is unknown to the surface population.  According to Platinum Studios Chairman Scott Mitchell Rosenberg, “’Atlantis Rising’ is a provocative sci-fi thriller that at its core brings up the question: whose planet is this?”

Atlantis Rising was created by Rosenberg and first published as a five-issue mini-series that had been previously optioned to Dreamworks.  The rights to production have been re-gained by Platinum Studios, paving the way for the up-and-coming film series.

Canton, who is also CEO of Atmosphere Entertainment, has seen success in his career on multiple occasions, such as Relativity’s “Immortals,” which has grossed more than $210 million in global box office sales.  Other recent works by Atmosphere have included Warner Bros’ “300,” Paramount Pictures “The Spiderwick Chronicles” and Summit’s “Letters to Juliet,” starring Amanda Sayfried and Vanessa Redgrave.

Canton sees some solid potential for the new movie series.

“’Atlantis Rising’ has the franchise potential of ‘Men in Black’ which I green lit for Scott while at Sony’s Columbia Tristar Motion Picture Companies,” says Mark Canton. “I’m looking forward to bringing it to the screen with Platinum as a dynamic, state of the art action thriller.”

The news may come at an opportune time for Platinum Studios. Shares of PDOS have been fighting to find a bottom since rising to 7.4 cents in July of last year. Appearing to once again find a bottom support in the area of $0.0015, shares are up more than 10 percent in today’s trading with a last price of $0.0021 with 90 minutes left in the trading day.

Platinum Studios (PDOS) Stock Quote and News:

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.